Alvotech
ALVO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ALVO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ALVO
Alvotech is a vertically integrated biotechnology company focused on developing and manufacturing biosimilar medicines, with a growing portfolio of approved products and a pipeline targeting major disease areas globally.
Key risk: High debt and negative equity
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
Tracking 2 clinical trials · 1 catalyst for Alvotech.
Alvotech is a vertically integrated biotechnology company focused on developing and manufacturing biosimilar medicines, with a growing portfolio of approved products and a pipeline targeting major disease areas globally.
- Alvotech is a vertically integrated biotechnology company focused solely on the development and manufacture of biosimilar medicines [sec · filed 2026-03-31].
- As of 2025-12-31, the company reported cash & equivalents of $172.4M, total revenue of $586.3M, and net income of $27.9M [sec].
- The company has a global network of commercial partnerships, including with Teva (U.S.), STADA (EU), Fuji Pharma (Japan), and JAMP Pharma (Canada) [sec · filed 2026-03-31].
- Alvotech has received marketing approvals for several biosimilars, including AVT02, AVT04, and three additional biosimilars in 2025 [sec · filed 2026-03-31].
- The company's BLA for AVT16, a proposed interchangeable biosimilar to Entyvio, was accepted for review by the FDA in June 2026 [sec · filed 2026-06-08].
What works
- Alvotech has built a comprehensive, vertically integrated platform for biosimilar development and manufacturing, having invested over $2 billion, which enables in-house execution from R&D through regulatory approvals [sec · filed 2026-03-31].
- The company has secured marketing approvals for multiple biosimilars in major markets, including the U.S., EEA, UK, Canada, and Japan, demonstrating regulatory execution capability [sec · filed 2026-03-31].
- Alvotech has established a global network of strategic commercial partnerships with leading pharmaceutical companies, providing local market expertise and broad geographic reach [sec · filed 2026-03-31].
What to weigh
- Alvotech has a significant accumulated deficit and negative shareholders' equity of -$564.4M as of 2025-12-31, reflecting historical losses and ongoing capital needs [sec].
- The company's total debt is $1,467.5M as of 2025-12-31, indicating a high leverage position that may require substantial future cash flows to service [sec].
- Alvotech's revenue is concentrated on a limited number of products and commercial partners, making it vulnerable to unfavorable changes in any single product, jurisdiction, or partner [sec · filed 2026-03-31].
- The company's financial statements include a going concern explanatory paragraph, highlighting uncertainty about its ability to continue without additional funding [sec · filed 2026-03-31].
From the filings
Quoted directly from source documents.
Alvotech is a vertically integrated biosimilar company with a global partnership network.
“integrated biotechnology company focused solely on the development and manufacture of biosimilar medicines for patients worldwide.”
SEC filings · March 31, 2026
Alvotech has received multiple marketing approvals for biosimilars in major markets.
“by the end of 2025 we also received marketing approvals for three additional biosimilars in 2025.”
SEC filings · March 31, 2026
Alvotech's BLA for AVT16 was accepted for FDA review.
“its Biologics License Application ("BLA") for AVT16, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) lyophilized vial for intravenous administration, has been accepted for review by the U.S. Food and Drug Administration.”
SEC filings · June 8, 2026
Alvotech has a going concern uncertainty.
“ited consolidated financial statements appearing elsewhere in this Annual Report have been prepared on a going concern basis without adjustments that might result from the outcome of this uncertainty”
SEC filings · March 31, 2026
Catalyst timeline
- 2028-01-01 · Phase3_Topline · eylea — Phase 3 Topline: A Randomized, Double-masked, Parallel-group, Multicenter Clinical Study to Evaluate the Efficacy and — Topline results from the Phase 3 study of AVT06 (aflibercept biosimilar) are expected, which will inform regulatory filing plans.
Risks & what to watch (4)›
Key risks
- High debt and negative equity — Total debt of $1,467.5M and negative shareholders' equity of -$564.4M as of 2025-12-31 [sec].
- Going concern uncertainty — Financial statements prepared on a going concern basis with an explanatory paragraph from auditors [sec · filed 2026-03-31].
- Revenue concentration risk — Revenue dependent on a limited number of products, jurisdictions, and commercial partners [sec · filed 2026-03-31].
- Regulatory approval delays — Uncertainty in scope, timing, and evidentiary requirements for marketing authorizations [sec · filed 2026-03-31].
What to watch
- FDA review outcome for AVT16 BLA, expected within six months from submission date in June 2026 [sec · filed 2026-06-08].
- Commercial performance of recently approved biosimilars (AVT03, AVT05, AVT06) in Japan and other markets [sec · filed 2026-03-31].
- Ability to secure additional funding or generate sufficient cash flow to address going concern and debt obligations [sec · filed 2026-03-31].
- Phase 3 topline results for AVT06 (aflibercept biosimilar) expected in 2028 [catalyst].
Sources: SEC filings · Generated August 26, 2026 · How we verify sources →
Run Alvotech through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Alvotech facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
17.5 months
OCF -$50M · Net income $28M
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~489d
No insider transactions in the last 180 days
Runway
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
55
Total value held
$54.0M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 6,820,894 | $23.7M |
| millennium management llc | 2,122,596 | $7.3M |
| littlejohn & co llc | 1,318,534 | $4.5M |
| blackrock, inc. | 1,245,195 | $4.3M |
| vanguard fiduciary trust co | 974,228 | $3.4M |
| legal & general group plc | 504,460 | $1.7M |
| geode capital management, llc | 324,199 | $1.1M |
| ubs group ag | 322,157 | $1.1M |
| oaktree capital management lp | 578,058 | $1.0M |
| morgan stanley | 243,277 | $834K |
Showing top 10 of 55 institutional holders of Alvotech. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 2.3%
- Days to cover
- 5.0
- Shares short
- 2,701,400
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ALVO short interestFrequently asked questions
What is the AI investment thesis for Alvotech?
Alvotech is a vertically integrated biotechnology company focused on developing and manufacturing biosimilar medicines, with a growing portfolio of approved products and a pipeline targeting major disease areas globally.
What is Alvotech's next catalyst?
Alvotech's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Double-masked, Parallel-group, Multicenter Clinical Study to Evaluate the Efficacy and" — expected January 1, 2028.
Who is the CEO of Alvotech?
Ms. Lisa Graver is the chief executive officer of Alvotech (ALVO).
Where is Alvotech headquartered?
Alvotech (ALVO) is headquartered in Luxembourg, Luxembourg.
What therapeutic areas does Alvotech focus on?
Alvotech develops therapies across Oncology, Immunology, Ophthalmology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.